サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1417424

メタボトロピックグルタミン酸受容体の世界市場：動向、予測、競合分析（～2030年）

Metabotropic Glutamate Receptor Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日
発行
Lucintel
ページ情報
英文 150 - page report
納期
3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.98円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

メタボトロピックグルタミン酸受容体の世界市場：動向、予測、競合分析（～2030年）
出版日: 2024年01月29日
発行: Lucintel
ページ情報: 英文 150 - page report
納期: 3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

メタボトロピックグルタミン酸受容体の動向と予測

世界のメタボトロピックグルタミン酸受容体の市場規模は、2024～2030年にかけてCAGR 11.0%で成長し、2030年までに推定23億米ドルに達すると予測されています。この市場の主な促進要因は、神経疾患の有病率の増加、可処分所得の増加、世界の高齢者人口の増加です。メタボトロピックグルタミン酸受容体の世界市場の将来は、注意欠陥多動性障害（ADHD）、アルツハイマー病、慢性閉塞性肺疾患（COPD）市場における機会で有望視されています。

メタボトロピックグルタミン酸受容体市場の洞察

Lucintel社は、mGlur5が予測期間中に最も高い成長を遂げると予測しています。

北米は、確立されたヘルスケアインフラの存在、研究資金の増加、同地域の神経疾患を患う膨大な患者数により、予測期間中に最も高い成長が見込まれています。

よくある質問

Q.1メタボトロピックグルタミン酸受容体の市場規模は？

A1.世界のメタボトロピックグルタミン酸受容体市場は、2030年までに推定23億米ドルに達すると予想されています。

Q.2メタボトロピックグルタミン酸受容体市場の成長予測は？

A2.世界のメタボトロピックグルタミン酸受容体市場は、2024～2030年にかけてCAGR 11.0％で成長すると予想されています。

Q.3メタボトロピックグルタミン酸受容体市場の成長に影響を与える主な促進要因は何ですか？

A3.この市場の主な促進要因は、神経疾患の有病率の増加、可処分所得の増加、世界の高齢者人口の増加です。

Q4.市場の主要セグメントは？

A4.注意欠陥多動性障害（ADHD）、アルツハイマー病、慢性閉塞性肺疾患（COPD）市場における機会により、世界のメタボトロピックグルタミン酸受容体市場の将来は有望と思われます。

Q5.市場の主要企業は？

A5.主要なメタボトロピックグルタミン酸受容体企業は以下の通りです。

  • Eli Lilly and Company
  • Novartis International
  • Prexton Therapeutics
  • Addex Therapeutics
  • Taisho Pharmaceutical Holding
  • Astrazeneca
  • Domain Therapeutic
  • Abcam
  • Johnson & Johnson
  • Medgenic

Q6.今後、最大となる市場セグメントは？

A6.Lucintel社は、mGlur5が予測期間中に最も高い成長を遂げると予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は？

A7.北米は、確立されたヘルスケアインフラの存在、研究資金の増加、同地域の神経疾患に罹患する膨大な患者数のため、予測期間中に最も高い成長を示すと予想されます。

Q8.レポートのカスタマイズは可能？

A8.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界のメタボトロピックグルタミン酸受容体市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 市場動向と予測分析：2018～2030年

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界のメタボトロピックグルタミン酸受容体の市場動向（2018～2023年）と予測（2024～2030年）
  • 世界のメタボトロピックグルタミン酸受容体市場：製品タイプ別
    • mGluR2
    • mGluR4
    • mGluR5
  • 世界のメタボトロピックグルタミン酸受容体市場：用途別
    • 注意欠陥多動性障害（ADHD）
    • アルツハイマー病
    • 慢性閉塞性肺疾患（COPD）

第4章 市場動向と予測分析：地域別（2018～2030年）

  • 世界のメタボトロピックグルタミン酸受容体市場：地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • 製品タイプ別
    • 用途別
    • 地域別
  • 世界のメタボトロピックグルタミン酸受容体市場における新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界のメタボトロピックグルタミン酸受容体市場の能力拡大
    • 世界のメタボトロピックグルタミン酸受容体市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Eli Lilly and Company
  • Novartis International
  • Prexton Therapeutics
  • Addex Therapeutics
  • Taisho Pharmaceutical Holding
  • Astrazeneca
  • Domain Therapeutic
  • Abcam
  • Johnson & Johnson
  • Medgenic
目次

Metabotropic Glutamate Receptor Trends and Forecast

The future of the global metabotropic glutamate receptor market looks promising with opportunities in the attention deficit hyperactivity disorder (ADHD), alzheimer's disease, and chronic obstructive pulmonary disease (COPD) markets. The global metabotropic glutamate receptor market is expected to reach an estimated $2.3 billion by 2030 with a CAGR of 11.0% from 2024 to 2030. The major drivers for this market are increase in the prevalence of neurological conditions, growth in disposable income and rise in the world's elderly population.

A more than 150-page report is developed to help in your business decisions.

Metabotropic Glutamate Receptor by Segment

The study includes a forecast for the global metabotropic glutamate receptor by product type, application, and region.

Metabotropic Glutamate Receptor Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

  • mGluR2
  • mGluR4
  • mGluR5

Metabotropic Glutamate Receptor Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Attention Deficit Hyperactivity Disorder
  • Alzheimer's Disease
  • Chronic Obstructive Pulmonary Disease

Metabotropic Glutamate Receptor Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • Europe
  • Asia Pacific
  • ROW

List of Metabotropic Glutamate Receptor Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies metabotropic glutamate receptor companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the metabotropic glutamate receptor companies profiled in this report include-

  • Eli Lilly and Company
  • Novartis International
  • Prexton Therapeutics
  • Addex Therapeutics
  • Taisho Pharmaceutical Holding
  • Astrazeneca
  • Domain Therapeutic
  • Abcam
  • Johnson & Johnson
  • Medgenic

Metabotropic Glutamate Receptor Market Insights

Lucintel forecasts that mGlur5 is expected to witness highest growth over the forecast period.

North America is expected to witness highest growth over the forecast period due to existence of well-established healthcare infrastructure, rise in research funding, huge patient pool suffering from neurological disorders in the region.

Features of the Global Metabotropic Glutamate Receptor Market

Market Size Estimates: Metabotropic glutamate receptor market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Metabotropic glutamate receptor market size by product type, application, and region in terms of value ($B).

Regional Analysis: Metabotropic glutamate receptor market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product type, application, and regions for the metabotropic glutamate receptor market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the metabotropic glutamate receptor market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the metabotropic glutamate receptor market size?

Answer: The global metabotropic glutamate receptor market is expected to reach an estimated $2.3 billion by 2030.

Q.2 What is the growth forecast for metabotropic glutamate receptor market?

Answer: The global metabotropic glutamate receptor market is expected to grow with a CAGR of 11.0% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the metabotropic glutamate receptor market?

Answer: The major drivers for this market are increase in the prevalence of neurological conditions, growth in disposable income and rise in the world's elderly population.

Q4. What are the major segments for metabotropic glutamate receptor market?

Answer: The future of the global metabotropic glutamate receptor market looks promising with opportunities in the attention deficit hyperactivity disorder (ADHD), alzheimer's disease, and chronic obstructive pulmonary disease (COPD) markets.

Q5. Who are the key metabotropic glutamate receptor market companies?

Answer: Some of the key metabotropic glutamate receptor companies are as follows.

  • Eli Lilly and Company
  • Novartis International
  • Prexton Therapeutics
  • Addex Therapeutics
  • Taisho Pharmaceutical Holding
  • Astrazeneca
  • Domain Therapeutic
  • Abcam
  • Johnson & Johnson
  • Medgenic

Q6. Which metabotropic glutamate receptor market segment will be the largest in future?

Answer: Lucintel forecasts that mGlur5 is expected to witness highest growth over the forecast period.

Q7. In metabotropic glutamate receptor market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to existence of well-established healthcare infrastructure, rise in research funding, huge patient pool suffering from neurological disorders in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the metabotropic glutamate receptor market by product type (mGlur2, mGlur4, and mGlur5), application (attention deficit hyperactivity disorder, alzheimer's disease, and chronic obstructive pulmonary disease), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Metabotropic Glutamate Receptor Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Metabotropic Glutamate Receptor Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Metabotropic Glutamate Receptor Market by Product Type
    • 3.3.1: mGluR2
    • 3.3.2: mGluR4
    • 3.3.3: mGluR5
  • 3.4: Global Metabotropic Glutamate Receptor Market by Application
    • 3.4.1: Attention Deficit Hyperactivity Disorder (ADHD)
    • 3.4.2: Alzheimer's Disease
    • 3.4.3: Chronic Obstructive Pulmonary Disease (COPD)

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Metabotropic Glutamate Receptor Market by Region
  • 4.2: North American Metabotropic Glutamate Receptor Market
    • 4.2.2: North American Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease, and Chronic Obstructive Pulmonary Disease
  • 4.3: European Metabotropic Glutamate Receptor Market
    • 4.3.1: European Metabotropic Glutamate Receptor Market by Product Type: mGluR2, mGluR4, and mGluR5
    • 4.3.2: European Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease, and Chronic Obstructive Pulmonary Disease
  • 4.4: APAC Metabotropic Glutamate Receptor Market
    • 4.4.1: APAC Metabotropic Glutamate Receptor Market by Product Type: mGluR2, mGluR4, and mGluR5
    • 4.4.2: APAC Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease, and Chronic Obstructive Pulmonary Disease
  • 4.5: ROW Metabotropic Glutamate Receptor Market
    • 4.5.1: ROW Metabotropic Glutamate Receptor Market by Product Type: mGluR2, mGluR4, and mGluR5
    • 4.5.2: ROW Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease,and Chronic Obstructive Pulmonary Disease

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Metabotropic Glutamate Receptor Market by Product Type
    • 6.1.2: Growth Opportunities for the Global Metabotropic Glutamate Receptor Market by Application
    • 6.1.3: Growth Opportunities for the Global Metabotropic Glutamate Receptor Market by Region
  • 6.2: Emerging Trends in the Global Metabotropic Glutamate Receptor Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Metabotropic Glutamate Receptor Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Metabotropic Glutamate Receptor Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Eli Lilly and Company
  • 7.2: Novartis International
  • 7.3: Prexton Therapeutics
  • 7.4: Addex Therapeutics
  • 7.5: Taisho Pharmaceutical Holding
  • 7.6: Astrazeneca
  • 7.7: Domain Therapeutic
  • 7.8: Abcam
  • 7.9: Johnson & Johnson
  • 7.10: Medgenic